The development of monoclonal antibody (mAb) therapeutics requires fast turnaround of testing results to drive decision making during process development. Through the automation of routine testing assays, turnaround time has been reduced from 2 weeks to 1, yet laboratory processes are still hindered by preparative steps where samples are received, organized, and handled manually. By introducing new equipment, labware, and automated data handling, samples can be quickly processed through a myriad of product quality tests. These tools have further streamlined testing, reducing post-purification sample logistics to 1 hour and assay preparation to 30 minutes. These newfound efficiencies empower 1- to 2-day turnaround times, which further promote study design and impact in cell culture development.
